Global RNA-interference (RNAi) Market Size (2024 - 2029)

RNAi Technology Market Analysis

The Global RNA-interference Market size is estimated at USD 1.36 billion in 2024, and is expected to reach USD 2.9 billion by 2029, growing at a CAGR of 16.29% during the forecast period (2024-2029).

COVID-19 is expected to have a significant impact on the growth of the market. The demand for RNA interference is expected to increase as it is effectively used for the development of COVID-19 disease therapeutics. According to the article titled 'Prospects for RNAi therapy of COVID-19' published in July 2020, RNAi against COVID-19 disease can potentially be directed against two different categories of targets such as viral proteins essential in survival and replication of SARS-CoV-2 and Host factors involved in cellular entry and trafficking of the virus. Such potential benefits of RNA interference for the development of COVID-19 therapy is expected to drive the growth of the market.

Certain factors that are driving the market growth include the increasing number of applications in molecular diagnostics, particularly in cancer, and improving synthetic delivery carriers and chemical modifications to RNA.

Cancer diagnosis and treatment are currently undergoing a shift with the incorporation of RNAi techniques in personalized medicine and molecular diagnostics. The availability of high throughput techniques for the identification of altered cellular molecules and metabolites allows the use of RNAi techniques in various cancer diagnosis and targeting approaches. According to the article titled ' Insight into the prospects for RNAi Therapy of Cancer' published in March 2021 the expression of terget genes is knocked by RNAi, locating these nodes which are insipensable to tumor maintenance, with low side effects and low risk, blocking the inherent immunosuppression and triggering immune attacks on tumors. Moreover one of the advantages of RNAi technology is the rapid development of efficacious and targeted drugs for controlling tumor growth. For diagnostic purposes, small interfering RNAs (siRNA) or microRNAs (miRNA) can be utilized. The commercial availability of siRNAs to silence virtually any gene in the human genome is dramatically accelerating the pace of molecular diagnosis and biomedical research. For instance in December 2020 expanded its existing cooperation scope, including the development and commercialization of RNAi therapeutic drugs. the company used its latest progress in targeted delivery of siRNA drugs and its established capabilities to deepen the development of RNAi drugs for tumors and neurological diseases. Thus, increasing the application of RNAi in molecular diagnosis and its viability as a therapeutic technique may boost the growth of the RNAi market.

Thus the above mentioned factors are expected to fuel the growth of the market during the forecast period.

RNAi Technology Industry Segmentation

RNA interference is a biological process in which the RNA molecules are observed to inhibit gene expression or translation, by neutralizing the targeted mRNA molecules. Earlier, RNAi was identified by other names, such as co-suppression, post-transcriptional gene silencing (PTGS), and quelling. The extensive study of each of these apparently different processes clarified that the identity of these phenomena was all in fact RNAi. The RNA-interference (RNAi) market is segmented by Application (Drug Discovery and Development, Therapeutics [Oncology, Ocular Disorders, Respiratory Disorders, Hepatitis B and C, Autoimmune Hepatitis, Neurological Disorders, and Other Therapeutics]) and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.